Alpha Tau Medical Ltd.
DRTS · Nasdaq · USD · Market cap $1.1B · 121 employees
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price11.76 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 8.18)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $16.00 to $23.51, base estimate $18.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 8.18, read 2026-11-20
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Alpha Tau Medical Ltd. holds its Markup at $11.76. The statistical read favours the sellers, held for 63 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 63 days |
| Price at the screen | $11.76 |
| Valuation | N/A trailing · -21.88 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.29 |
Five Screens: DRTS's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 12.99% | Below 33% | Pass |
| Interest-bearing cash | 57.66% | Below 33% | Fail |
| Receivables | 11.87% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Alpha Tau Medical's business is fine, but its cash and interest-bearing securities are about 58% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when DRTS's ethical verdict changes
Today DRTS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 35% discount to our $18.00 fair value.
USD, 2026-11-20 screen. A 34.7% under base.
Street: 5 covering, consensus Strong Buy. Average target +53%.
| Forward P/E | -21.9x |
| EPS, trailing | -1.04 |
| EPS, forward | -0.54 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -141.7%not currently earning a positive return on equity |
| FCF yield | -1.86% |
| Debt to equity | 0.34minimal debt: a conservative balance sheet |
| Current ratio | 11.09comfortably covers its short-term bills |
| Beta | 1.29moves a little more than the market |
| Short interest, float | 0.06% |
| 52-week range | 3.43 - 15.79 |
| Market cap | $1.1B |
| Employees | 121 |
DRTS-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Earnings landed in this window.
The framework has shifted from markdown to distribution since the last review. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial Yahoo Finance · 9d ago
- Alpha Tau Medical (DRTS) Stock May Be Hard To Justify Despite Its 343% Run Yahoo Finance · 15d ago
- Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange Yahoo Finance · 23d ago
- Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea Yahoo Finance · 22 Oct 2026
- How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial Yahoo Finance · 21 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $10.34 | -11.8% | · | $882 | -11.8% |
| 2 months | $7.29 | +25.1% | · | $1,251 | +25.1% |
| 3 months | $6.97 | +30.9% | · | $1,309 | +30.9% |
| 6 months | $4.96 | +83.9% | · | $1,839 | +83.9% |
| 1 year | $3.09 | +195.2% | · | $2,952 | +195.2% |
| 2 years | $2.38 | +283.2% | · | $3,832 | +283.2% |
| 3 years | $4.00 | +128.0% | · | $2,280 | +128.0% |
| 5 years | $9.65 | -5.5% | · | $945 | -5.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever DRTS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.